VHVira Health Financial Model
Biotech/Pharma Startup Financials (Free Excel Download)
Digital menopause care platform ("Stella") combining a personalised 12-week behaviour-change app with 1:1 coaching, community, and a roadmap to add telemedicine and pharmaceutical prescription/delivery.
professionals from Deloitte
Used by professionals from
About this model
Vira Health’s Stella platform provides digital menopause care through a personalised 12-week behaviour-change programme, one-to-one coaching, symptom-specific meditation and music, and an online community. The product addresses symptoms including anxiety, hot flushes, insomnia, fatigue, stress, pain, and loss of focus while aiming to make personalised menopause support more accessible.
The initial commercial model is a direct-to-consumer subscription app; pricing was not disclosed in the source research. Vira’s roadmap adds specialist telemedicine consultations and automated HRT prescription delivery, creating future consultation and fulfilment revenue streams around the core digital care relationship. The research identifies a large underserved UK menopause population but does not disclose subscriber or retention metrics.
The financial model should forecast app subscribers, subscription revenue, acquisition cost, coaching capacity, and retention. It should then layer in telemedicine attachment, consultation frequency, prescription fulfilment margin, and clinical operations as the service broadens. Scenarios can test the pace of consumer adoption, care-team hiring, medical-service launch timing, and the contribution of each additional revenue stream.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
About Vira Health
How to build a detailed financial model for Vira Health
A complete walkthrough of the business, drivers, and assumptions behind the downloadable Vira Health model - distilled from its pitch deck and publicly available information.
Product & value proposition
- Core product: "Stella" mobile app
- Behaviour change: 12-week programme personalised to symptom profile (anxiety, hot flush, insomnia, fatigue, stress, feeling down, pain relief, focus)
- Immediate relief: Meditation and music tracks targeting specific symptoms
- Coach: 1:1 human coaching supported by automation
- Community: Stella Lives, Q&As, articles, stories, recipes, exercises
- Roadmap (planned, not yet launched): telemedicine (video/phone specialist consultations) and pharmaceutical arm (automatic HRT prescription + delivery) to complete the full care pathway
- Mission: make personalised menopause care the norm; reduce long-term impact of osteoporosis, cardiovascular disease, diabetes and dementia
Market
- TAM: $600 billion global menopause market
- Population: 1.1 billion women coping with menopause worldwide
- UK addressable: 13 million UK women in menopause; only 910,000 (~7%) say they currently receive adequate care
Revenue model
- Primary model: Consumer subscription app (Stella). Pricing not stated in deck.
- Planned revenue streams (roadmap):
- Telemedicine consultations (per-session or subscription top-up)
- Pharmaceuticals / HRT prescription and delivery (likely per-prescription or recurring fulfilment margin)
- Channel: Direct-to-consumer via mobile app
- No B2B / employer channel mentioned in deck
Traction & metrics
- User feedback: Testimonials from 6 named users (Yvonne 56, Laura 60, Joanne 45, Adele 52, Nikki 48, Helen 51) - qualitative only, no user count or retention figure
- Described as "early feedback" - implies product is live but user base small
- No revenue figure, subscriber count, MRR/ARR, download numbers, or NPS score disclosed in deck
Competition / moat
- Moat implied but not explicitly named:
- Clinical credibility: co-founder has Medical Science PhD (Cambridge), health consultant to Mayor of London, UNICEF, WHO, PHE
- Strategic positioning: full-pathway vision (behaviour change → telemedicine → pharmacy) creates data lock-in
- Media / brand: extensive press coverage (Guardian, FT, NYT, TED) cited as validation of timing
- No direct competitor comparison slide in deck
Team & funding ask / use of funds
- Andrea Berchowitz, Co-founder & CEO: 10+ years McKinsey, Bill & Melinda Gates Foundation, TED Speaker on menopause
- Dr Rebecca Love, Co-founder & CPO: Medical Science PhD Cambridge, health consultant to Mayor of London, UNICEF, WHO, PHE
Recommended financial model
- Archetype + why: B2C subscription + marketplace / clinic revenue model. Stella has a classic freemium-or-paid subscription core (app), with a second revenue layer from telemedicine (per-consultation or bundled) and a third from pharmaceutical fulfilment (margin on prescriptions). The appropriate archetype is a 3-stream subscription + services P&L - analogous to a digital health subscription with a care marketplace bolt-on (similar to Hims/Hers or Noom). A full 3-statement model is premature without funding disclosures, so an operating forecast (P&L + cash burn) is the right output.
- Forecast horizon & granularity: 5 years (Year 1–5); monthly granularity for Year 1–2, then annual for Year 3–5. Early months are pre-scale, so monthly detail matters for cash runway.
- Key drivers & assumptions:
| Driver | Value |
|---|---|
| UK addressable women in menopause | 13,000,000 |
| % currently receiving adequate care | 7% |
| App subscription price (monthly) | £15–£25/month |
| Annual subscription price (if offered) | £120–£180/year |
| Free trial / onboarding conversion rate | 15–25% |
| Monthly churn | 5–8% |
| CAC (paid digital) | £30–£60 |
| Gross margin - app subscription | 75–80% |
| Telemedicine consult price | £50–£80 per session |
| Telemedicine gross margin | 40–50% |
| Pharmacy/HRT fulfilment margin | 20–30% |
| Telemedicine launch timing | Year 2 |
| Pharmacy launch timing | Year 3 |
| Headcount ramp | 5 FTE Year 1 → 20 FTE Year 3 |
| Avg salary (UK) | £60,000 fully loaded |
- Scenarios (Base / Bull / Bear - which variables flex):
- Base: 5% monthly subscriber growth, 6% churn, £20/month ARPU, telemedicine in Year 2
- Bull: 10% monthly subscriber growth, 4% churn, upsell to telemedicine/pharmacy drives ARPU to £35+/month equivalent
- Bear: 2% monthly subscriber growth, 9% churn, telemedicine delayed to Year 3, higher CAC (£80)
- Required sheets / outputs:
- Assumptions - all drivers with scenario toggles (Base/Bull/Bear)
- Subscribers - monthly cohort model (new subs, churn, ending users per product tier)
- Revenue - app subscription + telemedicine + pharmacy by month/year
- P&L - gross profit, S&M (CAC × new users), R&D, G&A, EBITDA
- Cash & Runway - opening cash (to be filled once funding disclosed), monthly burn, runway in months
- Unit Economics summary - LTV, CAC, LTV:CAC, payback period
- Dashboard - KPI summary (MRR, subscribers, churn, burn, runway)
Frequently asked
Is the Vira Health financial model free?+
Yes. The Vira Health model is a free Excel (.xlsx) download with live formulas. Sign up with your email and the workbook is yours to keep, review, and edit.
What's included in the model?+
A 5-year monthly forecast with P&L, cash flow and runway, valuation (exit multiple plus a DCF cross-check), MOIC/IRR returns, and unit economics, with live formulas throughout.
How was this model built?+
It was built from Vira Health's pitch deck and publicly available information, then structured to investment-banking standards as a fully editable Excel model.
Can I change the assumptions?+
Yes. You can change assumptions and the live formulas will recalculate in the downloadable Excel model.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Biotech/Pharma Startup Financial Models
Browse another startup in the same category.
Ada Health
AI-powered symptom assessment app and clinical decision-support platform for consumers and healthcare partners.
Affini-T
Engineered T cell therapies targeting oncogenic driver mutations (KRAS, p53) in hard-to-treat solid tumors
Alto Pharmacy
Alto Pharmacy is a tech-enabled, same-day prescription delivery pharmacy disrupting the $450B US pharmacy market via a direct-to-patient courier model and provider-facing software platform.
Aphea.Bio
Aphea.Bio is a Belgian ag-biotech company developing and commercialising microbial biologicals (biostimulants, biofungicides, bioherbicides, bioinsecticides) for row crops, targeting yield improvement and reduced synthetic input use.
Aurion Biotech
Cell therapy company developing an injectable corneal endothelial cell treatment to restore vision in patients with corneal endothelial disease.
Beckley Psytech
Clinical-stage psychedelic drug development platform advancing a pipeline of psychedelic compounds (psilocybin, 5-MeO-DMT, NCEs) as licensed pharmaceutical medicines for neuropsychiatric disorders.
BrightInsight
Regulated digital health platform-as-a-service for biopharma and medtech companies to build, launch, and maintain compliant connected-drug and medical-device software products.
Carrum Health
Value-based care marketplace connecting self-insured employers to top-tier surgical and oncology Centers of Excellence (COEs) via all-inclusive bundled payments.
